Skip to main content

Domainex expands analytical chemistry capabilities with over £1M worth of new Waters equipment

Domainex in the lab

Cambridge, United Kingdom, 3rd March 2022 / Domainex Ltd., a leading integrated medicines research services partner, announces that it has purchased over £1M worth of new Waters equipment to enhance its capabilities in analytical chemistry, bioanalytical sciences and in vitro absorbance, distribution, metabolism and excretion (ADME) assays. The new equipment will allow Domainex to increase its capacity and throughput, supporting its ongoing growth.

Included in the new equipment are two ACQUITY UPLC systems (one with an evaporative light scattering detector (ELSD) and one with a single quadrupole (SQ) detector), three mass-directed auto-purification systems (one with an SQ detector), and a highly sensitive Xevo TQ-XS triple quadrupole mass spectrometer.

The SQ detectors will enable Domainex to increase its capacity to analyse and purify compounds with higher molecular masses such as proteolysis targeting chimeras (PROTACs). The Xevo TQ-XS will allow Domainex to expand its range of in vitro ADME services to include hepatocyte stability assessments and permeability studies. To provide a continuous supply of high-quality nitrogen to the Xevo TQ-XS, Domainex has also purchased a new HF30A Generator from Chromalytic. The recent investment complements the existing suite of Waters analytical instrumentation already utilised at Domainex.

The purchase of this new equipment follows a recent expansion for Domainex, including the opening of a new facility at Unity Campus. Commenting on the capital purchases, Dr Tom Mander, CEO of Domainex, said: “We have an ambitious capital investment programme planned for 2022 which we are funding from our profits. We are seeing strong demand for our range of bioanalytical chemistry services. This significant capital investment will give our analytical chemistry team access to state-of the art technologies to provide high quality data to our clients. This expansion will allow us to continue to fully support our integrated drug discovery programmes. We have used Waters equipment for many years and have always been pleased with the quality of their products and the first class support they provide us.”

Joe Kildunne, Director for Pharmaceutical Marketing at Waters, commented: “It is a pleasure to partner with Domainex, an organisation who understands the need to provide best in class scientific solutions for their sponsors. At Waters we are passionate about providing our customers with the tools and support they need to grow their scientific capabilities and their business success.’’

ENDS

Notes to editors

About Domainex Ltd.

Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organizations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.

Domainex provides innovative and customized biology and chemistry services to advance the disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximizes the chance of successful progression for its partners’ research. Domainex’s innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing ideas, know-how and a wealth of experience to bear on their projects.

Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on over 60 patent applications of numerous candidate drugs. The Company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.

Full information about Domainex and its award-winning services can be found at www.domainex.co.uk

About Waters Corporation

Waters Corporation is the world's leading specialty measurement company focused on improving human health and well-being through the application of advanced analytical science technologies.

With approximately 7,500 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries. In a global, interconnected world full of questions, Waters’ innovation, service, and quality delivers confidence.

Waters creates business advantages for laboratory-dependent organizations by delivering practical and sustainable scientific innovations. Waters products are used by pharmaceutical, health science, food and environmental testing, chemical, industrial, contract laboratory, academic, and government organizations working in research and development, quality assurance and other laboratory applications. Waters’ chromatography and mass spectrometry instruments, software, and chemistry consumables are used in a broad range of industries to measure the chemical, physical, and biological composition of materials.

Find out more: www.waters.com

For more information, contact:

Domainex
Dr. Tom Mander, CEO
E: 
tom.mander@domainex.co.uk

Sciad Communications
Jasmin Shearan / Juliette Craggs / Darya Shulakova
T: +44 (0)20 3405 7892
E: domainex@sciad.com

Start your next project with Domainex

Contact one of our experts today